Shortage of Sufentanil Citrate Injection: FDA Status Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Sufentanil Citrate Injection is currently listed in the FDA Drug Shortage Database, with one manufacturer reporting availability as of March 27, 2026.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 8, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Sufentanil Citrate Injection.
What's in Shortage
The drug in shortage is Sufentanil Citrate Injection. Its generic name is Sufentanil Citrate Injection, and the brand name is SUFENTANIL CITRATE. The dosage form is Injection, and the current status is Current. It falls under the therapeutic categories of Analgesia/Addiction and Pediatric. The shortage was first posted on May 3, 2022, and last updated on March 27, 2026.
Which Manufacturers Are Affected
The affected manufacturer is Hospira, Inc., a Pfizer Company. Their availability status is Available for the presentation Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21). Contact information for this manufacturer is 844-646-4398.
Why There's a Shortage
No specific reason was provided for the shortage.
What Patients Should Do
Patients who depend on this medication should speak with their pharmacist or healthcare provider to check on availability and discuss options. They can contact the manufacturer for more details. Please remember that patients should consult their healthcare provider for any guidance and not make changes to their medication without professional advice.
Source
This information is from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,205 characters here).
Similar severity timing
Same severity (low) notices issued closest in time to April 8, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.